Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of RAD001 [everolimus] in combination with temozolomide in patients with advanced pancreatic neuroendocrine tumors

Trial Profile

Phase I/II study of RAD001 [everolimus] in combination with temozolomide in patients with advanced pancreatic neuroendocrine tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs Everolimus (Primary) ; Temozolomide (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Oct 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
    • 31 Oct 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Jun 2019.
    • 03 Aug 2017 Planned End Date changed from 1 Jul 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top